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E osinophils are innate immune cells belonging to the granulocytic compartment of circulating WBCs. Although they were identified more than a century ago in blood, sputum, and lung lavage samples, they remain a controversial cell type for their role in immunity, particularly in lung immune responses. Several studies using congenitally eosinophil-deficient strains of mice, PHIL, DdblGATA, and iPHIL, have demonstrated a prominent role for pulmonary eosinophils in regulating immune responses in allergic asthma as well as in pulmonary fibrosis, although some reports have cast these findings into doubt [1] [2] [3] . Possible reasons for the discrepancy in these reports may be that the three eosinophil-deficient strains of mice so far developed rely on the use of cytocidal reagents (diphtheria toxin) or gene targeting of key transcription factors (i.e., GATA-1). Potential confounding effects of these strategies could obscure our understanding of eosinophil effector functions in lung pathologies.
Recently, a novel, double-knockout mouse strain of two gene products that are almost exclusively expressed in eosinophils, MBP-1 and EPX, was shown to result in eosinophil deficiency with no apparent effects on other leukocyte lineages [4] . Single-gene knockouts of MBP-1 and EPX were shown to have no effects on AHR or pulmonary health [5] . Interestingly, unlike the single-gene knockout strains, eosinophil progenitors that lack genes expressing both of the key granule proteins MBP-1 and EPX exhibit negative feedback that blocks critical steps in the transcriptional development program in eosinophils, ultimately leading to a massive loss of mature eosinophils from the circulation and peripheral tissues. Thus, there is a tightly controlled feedback mechanism between granule formation and eosinophilopoiesis that regulates the development and maturation of eosinophils, potentially involving the transcription factor XBP-1 [6] as well as cystatin F [7] . The resulting eosinophil deficiency in the MBP-1 2/2 /EPX 2/2 strain, with its reduced risk of off-target effects, would, therefore, be ideal for studying models of eosinophilic diseases, without the need for cytocidal reagents or targeting of transcription factors; have broad tissue specificity; and hopefully, go some way toward resolving lingering doubts surrounding the role of eosinophils in lung disease. In this issue, Ochkur et al. [8] report important findings in the Journal of Leukocyte Biology showing that the double-knockout of MBP-1 and EPX results in the loss of salient features of eosinophil-associated pulmonary diseases, measured as AHR, inflammation of lung tissues leading to mucus overproduction (measured as GM/MA in lung sections), and reduced IL-4 and IL-13 production in the airways, similar to what has been observed in PHIL, DdblGATA, and iPHIL strains (Fig. 1) .
First, the MBP-1 2/2 /EPX 2/2 doubleknockout mice were subjected to an acute model of allergen sensitization and challenge using OVA, followed by methacholine challenge, which is an acute model of asthma that has been conventionally used to understand immune mechanisms of allergic airway inflammation. An interesting comparison in eosinophil degranulation responses was made between the two models of allergic airway inflammation and the I5/hE2 mouse strain. In the former model, OVA sensitization and challenge usually exhibits minimal eosinophil degranulation, whereas extensive eosinophil degranulation is evident in the I5/hE2 strain. In comparing these two mouse models, degranulation does not appear to contribute to AHR, whereby the loss of AHR was equivalent in the allergen-challenged (which lack degranulation) and I5/hE2 mice (with extensive degranulation). On the other hand, eosinophil degranulation appears to contribute more to the development of pulmonary fibrosis (measured as GM/MA) because a more-pronounced decrease in GM/MA was observed in I5/hE2/MBP-1 2/2 /EPX 2/2 mice compared with OVA-challenged MBP-1 2/2 / EPX 2/2 mice. The association of eosinophils with development of pulmonary fibrosis was originally reported in DdblGATA mice on a BALB/c background, in which the lack of eosinophils did not affect lung inflammation but, instead, reduced long-term remodeling [10] . These findings indicate that eosinophil degranulation may be a greater contributor to airway remodeling than AHR, although a direct comparison was not made between these models. A strength of these findings is that two distinct disease models were used to test the effect of MBP-1 and EPX double-gene deletion in airway physiology and responses, and both models support a critical role for eosinophils in lung disease, specifically in relation to AHR and mucus production. One would infer that this would not be necessary, given the previous findings in earlier mouse models; however, there have been concerns that eosinophil-deficient strains of mice do not show consistent results regarding the role of eosinophils in allergic asthma and other lung diseases [1] [2] [3] . Moreover, strain-specific differences (C57BL/6 vs. BALB/c) in these eosinophil-deficient mouse models contribute to the controversy surrounding the role of eosinophils in allergic lung inflammation [11] . Another important consideration is that the OVA model of allergic inflammation is being supplanted by the house dust mite extract model, which is thought to better reflect human disease, and this may also reveal differences in the role that eosinophils may have in allergic lung inflammation.
Although findings from the MBP-1 /EPX 2/2 mouse strain will go some way toward resolving differences reported in other studies. In light of these findings, we must always remain mindful of the possibility of spontaneous off-target mutations that may arise in ES cells or later, during breeding because of gene knockouts, particularly when more than one gene is ablated because these may still result in confounding effects [12] . However, the MBP-1 2/2 /EPX 2/2 double-knockout strain used in the present study was backcrossed on the C57Bl/6 background for at least 20 generations, which should reduce the incidence of unwanted, spontaneous mutations or other off-target effects in this strain.
In conclusion, this report provides further definitive evidence that eosinophils have an essential role in allergic airway inflammation and pulmonary pathologies related to tissue eosinophilia in the airways leading to tissue remodeling and fibrosis. Findings from this study should play down fears that the observed eosinophil-dependent airway remodeling and immune modulation in eosinophil-deficient strains of mice is an artifact of diphtheria toxin treatment or off-target effects resulting from gene deletion of the GATA-1 transcription factor. The results presented in this report will serve to extend previous studies, and they continue to support a prominent role for the enigmatic eosinophil in allergic airway inflammation. Indeed, clinical findings using the anti-IL-5 Ab treatment to deplete eosinophils in asthmatic subjects suggest that targeting eosinophils is beneficial for the treatment and management of allergic disease [13] . Perhaps the moral of these mouse models is that they reveal distinct aspects of allergic lung inflammation in an outbred human population. Future studies using the MBP-1 2/2 /EPX 2/2 mouse strain are anticipated, which will allow us gain a greater understanding of the specific function of eosinophils in immunity, which remains elusive, in spite of extensive experimental analysis using animal models.
